Taiyen Biotech Co Ltd (1737) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Taiyen Biotech Co Ltd (1737) has a cash flow conversion efficiency ratio of 0.028x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$194.08 Million ≈ $6.11 Million USD) by net assets (NT$6.81 Billion ≈ $214.67 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Taiyen Biotech Co Ltd - Cash Flow Conversion Efficiency Trend (2003–2025)
This chart illustrates how Taiyen Biotech Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Taiyen Biotech Co Ltd for a breakdown of total debt and financial obligations.
Taiyen Biotech Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Taiyen Biotech Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dynamix Corporation III Class A Ordinary Shares
NASDAQ:DNMX
|
9.652x |
|
Bergbahnen Engelberg Truebsee Titlis Bet AG
SW:TIBN
|
0.062x |
|
Maritime Resources Corp.
V:MAE
|
0.038x |
|
Yantai Changyu Pioneer Wine
SHE:200869
|
0.020x |
|
Jw Holdings
KO:096760
|
0.118x |
|
RCI Hospitality Holdings Inc
NASDAQ:RICK
|
0.051x |
|
GENFIT S.A. ADR/1 EO-25
F:XUPB
|
N/A |
|
X-Legend Entertainment Co Ltd
TW:4994
|
0.036x |
Annual Cash Flow Conversion Efficiency for Taiyen Biotech Co Ltd (2003–2025)
The table below shows the annual cash flow conversion efficiency of Taiyen Biotech Co Ltd from 2003 to 2025. For the full company profile with market capitalisation and key ratios, see 1737 market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$6.81 Billion ≈ $214.67 Million |
NT$473.77 Million ≈ $14.93 Million |
0.070x | -29.77% |
| 2024-12-31 | NT$6.67 Billion ≈ $210.07 Million |
NT$660.12 Million ≈ $20.80 Million |
0.099x | +42.64% |
| 2023-12-31 | NT$6.55 Billion ≈ $206.32 Million |
NT$454.54 Million ≈ $14.32 Million |
0.069x | -20.37% |
| 2022-12-31 | NT$6.66 Billion ≈ $209.89 Million |
NT$580.69 Million ≈ $18.29 Million |
0.087x | -5.39% |
| 2021-12-31 | NT$6.51 Billion ≈ $205.21 Million |
NT$600.08 Million ≈ $18.91 Million |
0.092x | +72.78% |
| 2020-12-31 | NT$6.36 Billion ≈ $200.51 Million |
NT$339.36 Million ≈ $10.69 Million |
0.053x | -0.82% |
| 2019-12-31 | NT$6.15 Billion ≈ $193.85 Million |
NT$330.81 Million ≈ $10.42 Million |
0.054x | -26.43% |
| 2018-12-31 | NT$6.16 Billion ≈ $193.93 Million |
NT$449.83 Million ≈ $14.17 Million |
0.073x | -27.65% |
| 2017-12-31 | NT$6.02 Billion ≈ $189.62 Million |
NT$607.87 Million ≈ $19.15 Million |
0.101x | +6.43% |
| 2016-12-31 | NT$5.99 Billion ≈ $188.60 Million |
NT$568.06 Million ≈ $17.90 Million |
0.095x | +44.86% |
| 2015-12-31 | NT$5.86 Billion ≈ $184.65 Million |
NT$383.93 Million ≈ $12.10 Million |
0.066x | +2.83% |
| 2014-12-31 | NT$5.82 Billion ≈ $183.52 Million |
NT$371.06 Million ≈ $11.69 Million |
0.064x | +79.77% |
| 2013-12-31 | NT$5.73 Billion ≈ $180.67 Million |
NT$203.21 Million ≈ $6.40 Million |
0.035x | +49.72% |
| 2012-12-31 | NT$6.53 Billion ≈ $205.60 Million |
NT$154.46 Million ≈ $4.87 Million |
0.024x | -36.43% |
| 2011-12-31 | NT$6.61 Billion ≈ $208.23 Million |
NT$246.09 Million ≈ $7.75 Million |
0.037x | -18.56% |
| 2010-12-31 | NT$6.58 Billion ≈ $207.34 Million |
NT$300.89 Million ≈ $9.48 Million |
0.046x | -16.13% |
| 2009-12-31 | NT$6.57 Billion ≈ $206.92 Million |
NT$358.02 Million ≈ $11.28 Million |
0.055x | -16.99% |
| 2008-12-31 | NT$6.36 Billion ≈ $200.31 Million |
NT$417.51 Million ≈ $13.15 Million |
0.066x | +35.05% |
| 2007-12-31 | NT$6.63 Billion ≈ $208.94 Million |
NT$322.49 Million ≈ $10.16 Million |
0.049x | -26.86% |
| 2006-12-31 | NT$6.96 Billion ≈ $219.34 Million |
NT$462.88 Million ≈ $14.58 Million |
0.066x | -20.34% |
| 2005-12-31 | NT$6.90 Billion ≈ $217.39 Million |
NT$575.91 Million ≈ $18.14 Million |
0.083x | -76.90% |
| 2004-12-31 | NT$7.85 Billion ≈ $247.21 Million |
NT$2.84 Billion ≈ $89.32 Million |
0.361x | -22.55% |
| 2003-12-31 | NT$7.33 Billion ≈ $230.91 Million |
NT$3.42 Billion ≈ $107.73 Million |
0.467x | -- |
About Taiyen Biotech Co Ltd
Taiyen Biotech Co., Ltd. engages in the production and sale of salt products in Taiwan and internationally. It offers beauty and skincare, and cleaning products; salt products; and leisure and pet foods, as well as health supplement. The company was founded in 1952 and is based in Tainan City, Taiwan.